Lorlatinib

CROWN

Lorlatinib CROWN

PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

PFS

ADJUSTMENTS

Quality of life

Not clinically significant

Serious and disabling adverse effects

Other adjustments

Long term plateau in the PFS curve

Lorlatinib CROWN

FINAL SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
Therapeutic Indication: Treatment of adult patients with anaplastic lymphoma kinase (ALK) positive (NSCLC) previously not treated with an ALK inhibitor
Experimental Arm: Lorlatinib
Control Arm: Crizotinib

© 2023 | **European Society for Medical Oncology** | ESMO - MCBS 1.1 | All rights reserved worldwide.